23.05 USD
+0.25 (+1.1%)
23.05 USD
0 (0%)
Overall PCRX gets a fundamental rating of 6 out of 10. We evaluated PCRX against 192 industry peers in the Pharmaceuticals industry. While PCRX has a great profitability rating, there are some minor concerns on its financial health. PCRX is cheap, but on the other hand it scores bad on growth. This makes PCRX very considerable for value investing!
1. Profitability
1.1 Basic Checks
PCRX had positive earnings in the past year.
PCRX had a positive operating cash flow in the past year.
PCRX had positive earnings in 4 of the past 5 years.
Each year in the past 5 years PCRX had a positive operating cash flow.
1.2 Ratios
PCRX's Return On Assets of 1.65% is amongst the best of the industry. PCRX outperforms 82.29% of its industry peers.
The Return On Equity of PCRX (2.95%) is better than 83.33% of its industry peers.
The Return On Invested Capital of PCRX (3.63%) is better than 81.77% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PCRX is significantly below the industry average of 13.48%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
With an excellent Profit Margin value of 2.99%, PCRX belongs to the best of the industry, outperforming 80.21% of the companies in the same industry.
With an excellent Operating Margin value of 8.88%, PCRX belongs to the best of the industry, outperforming 80.73% of the companies in the same industry.
In the last couple of years the Operating Margin of PCRX has grown nicely.
PCRX has a better Gross Margin (79.17%) than 83.33% of its industry peers.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
The number of shares outstanding for PCRX has been reduced compared to 1 year ago.
PCRX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PCRX is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.01 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.01, PCRX is doing good in the industry, outperforming 61.46% of the companies in the same industry.
The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
PCRX has a Debt to FCF ratio of 3.03. This is amongst the best in the industry. PCRX outperforms 90.10% of its industry peers.
PCRX has a Debt/Equity ratio of 0.52. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
The Debt to Equity ratio of PCRX (0.52) is worse than 61.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 2.01 |
ROIC/WACC0.49
WACC7.47%
2.3 Liquidity
A Current Ratio of 5.26 indicates that PCRX has no problem at all paying its short term obligations.
PCRX has a Current ratio of 5.26. This is in the better half of the industry: PCRX outperforms 66.67% of its industry peers.
PCRX has a Quick Ratio of 3.78. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
PCRX has a Quick ratio (3.78) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.90%.
PCRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.96% yearly.
PCRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.85%.
Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 10.73% on average per year.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
Based on estimates for the next years, PCRX will show a small growth in Earnings Per Share. The EPS will grow by 5.92% on average per year.
Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 5.45% on average per year.
EPS Next Y-8.75%
EPS Next 2Y1.59%
EPS Next 3Y6.02%
EPS Next 5Y5.92%
Revenue Next Year5.37%
Revenue Next 2Y7.75%
Revenue Next 3Y8.09%
Revenue Next 5Y5.45%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PCRX is valuated cheaply with a Price/Earnings ratio of 7.76.
PCRX's Price/Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 92.71% of the companies in the same industry.
When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (25.45), we can say PCRX is valued rather cheaply.
With a Price/Forward Earnings ratio of 6.96, the valuation of PCRX can be described as very cheap.
PCRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 94.27% of the companies in the same industry.
PCRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.76 | ||
| Fwd PE | 6.96 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 93.23% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, PCRX is valued cheaper than 91.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.34 | ||
| EV/EBITDA | 6.91 |
4.3 Compensation for Growth
The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.56
EPS Next 2Y1.59%
EPS Next 3Y6.02%
5. Dividend
5.1 Amount
PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.05
+0.25 (+1.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.55%
Inst Owner Change-5.56%
Ins Owners0.81%
Ins Owner Change-0.27%
Market Cap1.04B
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target37.74 (63.73%)
Short Float %16.51%
Short Ratio11.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)-1.07%
PT rev (3m)-1.07%
EPS NQ rev (1m)7.99%
EPS NQ rev (3m)8.62%
EPS NY rev (1m)0.7%
EPS NY rev (3m)1.33%
Revenue NQ rev (1m)-2.16%
Revenue NQ rev (3m)-1.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.76 | ||
| Fwd PE | 6.96 | ||
| P/S | 1.44 | ||
| P/FCF | 8.34 | ||
| P/OCF | 7.32 | ||
| P/B | 1.42 | ||
| P/tB | 3.19 | ||
| EV/EBITDA | 6.91 |
EPS(TTM)2.97
EY12.89%
EPS(NY)3.31
Fwd EY14.37%
FCF(TTM)2.76
FCFY11.99%
OCF(TTM)3.15
OCFY13.66%
SpS15.95
BVpS16.19
TBVpS7.22
PEG (NY)N/A
PEG (5Y)0.56
Graham Number32.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROCE | 5.34% | ||
| ROIC | 3.63% | ||
| ROICexc | 4.58% | ||
| ROICexgc | 7.99% | ||
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% | ||
| FCFM | 17.33% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.44 | ||
| Cap/Depr | 18.95% | ||
| Cap/Sales | 2.4% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 91.52% | ||
| Profit Quality | 579.36% | ||
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 2.01 |
F-Score7
WACC7.47%
ROIC/WACC0.49
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-8.75%
EPS Next 2Y1.59%
EPS Next 3Y6.02%
EPS Next 5Y5.92%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year5.37%
Revenue Next 2Y7.75%
Revenue Next 3Y8.09%
Revenue Next 5Y5.45%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year0.19%
EBIT Next 3Y7.79%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What are the PE and PB ratios of PACIRA BIOSCIENCES INC (PCRX) stock?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 7.76 and the Price/Book (PB) ratio is 1.42.
What is the financial health of PACIRA BIOSCIENCES INC (PCRX) stock?
The financial health rating of PACIRA BIOSCIENCES INC (PCRX) is 6 / 10.